{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:48:15Z","timestamp":1787240895273,"version":"build-2736575974"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["101000948"],"award-info":[{"award-number":["101000948"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["FDM202006011222"],"award-info":[{"award-number":["FDM202006011222"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-18-RHUS-005"],"award-info":[{"award-number":["ANR-18-RHUS-005"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["19-CE14-0030-01"],"award-info":[{"award-number":["19-CE14-0030-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007492","name":"Fondation Bettencourt Schueller","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012616","name":"Fondation Schlumberger pour l\u2019Education et la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012616","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.kint.2025.08.041","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T01:47:25Z","timestamp":1761788845000},"page":"64-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Drug repurposing in PIK3CA-related overgrowth spectrum: breakthroughs from overgrowth syndromes to kidney disease"],"prefix":"10.1016","volume":"109","author":[{"given":"Gabriel","family":"Morin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1880-7596","authenticated-orcid":false,"given":"Pierre","family":"Isnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Canaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2025.08.041_bib1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.kint.2025.08.041_bib2","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1126\/science.1096502","article-title":"High frequency of mutations of the PIK3CA gene in human cancers","volume":"304","author":"Samuels","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.kint.2025.08.041_bib3","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.ajhg.2012.05.006","article-title":"Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome","volume":"90","author":"Kurek","year":"2012","journal-title":"Am J Human Genet"},{"key":"10.1016\/j.kint.2025.08.041_bib4","series-title":"GeneReviews","article-title":"PIK3CA-related overgrowth spectrum","author":"Mirzaa","year":"2013"},{"key":"10.1016\/j.kint.2025.08.041_bib5","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.08.041_bib6","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41586-018-0217-9","article-title":"Targeted therapy in patients with PIK3CA-related overgrowth syndrome","volume":"558","author":"Venot","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.kint.2025.08.041_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.100969","article-title":"Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS)","volume":"25","author":"Canaud","year":"2023","journal-title":"Genet Med"},{"key":"10.1016\/j.kint.2025.08.041_bib9","doi-asserted-by":"crossref","DOI":"10.1172\/JCI176402","article-title":"PIK3CA inhibition in models of proliferative glomerulonephritis and lupus nephritis","volume":"134","author":"Yamaguchi","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2025.08.041_bib10","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nature05185","article-title":"Phosphoinositides in cell regulation and membrane dynamics","volume":"443","author":"Di Paolo","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.kint.2025.08.041_bib11","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1172\/JCI78945","article-title":"Phosphatidylinositol 3-kinase signaling determines kidney size","volume":"125","author":"Chen","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2025.08.041_bib12","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.stemcr.2015.01.021","article-title":"The PI3K pathway balances self-renewal and differentiation of nephron progenitor cells through \u03b2-catenin signaling","volume":"4","author":"Lindstr\u00f6m","year":"2015","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.kint.2025.08.041_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf1164","article-title":"Somatic PIK3CA mutations as a driver of sporadic venous malformations","volume":"8","author":"Castel","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.kint.2025.08.041_bib14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10549-020-05726-y","article-title":"Dermatologic adverse events related to the PI3K\u03b1 inhibitor alpelisib (BYL719) in patients with breast cancer","volume":"183","author":"Wang","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.kint.2025.08.041_bib15","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ajhg.2019.01.015","article-title":"Pharmacodynamic study of miransertib in individuals with Proteus syndrome","volume":"104","author":"Keppler-Noreuil","year":"2019","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.kint.2025.08.041_bib16","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3257","article-title":"Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies","volume":"137","author":"Adams","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.kint.2025.08.041_bib17","first-page":"1105","article-title":"Efficacy and tolerance of sirolimus (rapamycin) for extracranial arteriovenous malformations in children and adults","volume":"99","author":"Gabeff","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.kint.2025.08.041_bib18","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jvs.2019.06.217","article-title":"Efficacy and safety of sirolimus in the treatment of vascular anomalies: a systematic review","volume":"71","author":"Freixo","year":"2020","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.kint.2025.08.041_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamadermatol.2021.3459","article-title":"Sirolimus (rapamycin) for slow-flow malformations in children","volume":"157","author":"Maruani","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.kint.2025.08.041_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.173095","article-title":"Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations","author":"Seront","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.kint.2025.08.041_bib21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41574-019-0180-z","article-title":"Overgrowth syndromes \u2014 clinical and molecular aspects and tumour risk","volume":"15","author":"Brioude","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.kint.2025.08.041_bib22","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/ajmg.a.36552","article-title":"Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum","volume":"164","author":"Keppler-Noreuil","year":"2014","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.kint.2025.08.041_bib23","first-page":"211","article-title":"PIK3CA-related disorders: from disease mechanism to evidence-based treatments","volume":"25","author":"Morin","year":"2024"},{"key":"10.1016\/j.kint.2025.08.041_bib24","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1002\/ajmg.a.32023","article-title":"Newly delineated syndrome of congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE syndrome) in seven patients","volume":"143A","author":"Sapp","year":"2007","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.kint.2025.08.041_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MCD.0b013e328317a716","article-title":"Characterization of a distinct syndrome that associates complex truncal overgrowth, vascular, and acral anomalies: a descriptive study of 18 cases of CLOVES syndrome","volume":"18","author":"Alomari","year":"2009","journal-title":"Clin Dysmorphol"},{"key":"10.1016\/j.kint.2025.08.041_bib26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/CIRCRESAHA.121.318145","article-title":"Genetic basis and therapies for vascular anomalies","volume":"129","author":"Queisser","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.kint.2025.08.041_bib27","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/gim.2017.228","article-title":"Urine cell-free DNA is a biomarker for nephroblastomatosis or Wilms tumor in PIK3CA-related overgrowth spectrum (PROS)","volume":"20","author":"Biderman Waberski","year":"2018","journal-title":"Genet Med"},{"key":"10.1016\/j.kint.2025.08.041_bib28","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/cge.14410","article-title":"Low risk of embryonic and other cancers in PIK3CA-related overgrowth spectrum: impact on screening recommendations","volume":"104","author":"Faivre","year":"2023","journal-title":"Clin Genet"},{"key":"10.1016\/j.kint.2025.08.041_bib29","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41436-018-0297-9","article-title":"Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum","volume":"21","author":"Parker","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.kint.2025.08.041_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg0809","article-title":"Alpelisib administration reduced lymphatic malformations in a mouse model and in patients","volume":"13","author":"Delestre","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.kint.2025.08.041_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-024-01862-9","article-title":"Targeted therapy for capillary-venous malformations","volume":"9","author":"Zerbib","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.kint.2025.08.041_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade7823","article-title":"PIK3CA gain-of-function mutation in adipose tissue induces metabolic reprogramming with Warburg-like effect and severe endocrine disruption","volume":"8","author":"Ladraa","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.kint.2025.08.041_bib33","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230926","article-title":"Hemifacial myohyperplasia is due to somatic muscular PIK3CA gain-of-function mutations and responds to pharmacological inhibition","volume":"220","author":"Bayard","year":"2023","journal-title":"J Exp Med"},{"key":"10.1016\/j.kint.2025.08.041_bib34","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/sj.ki.5002691","article-title":"Nephrin mediates actin reorganization via phosphoinositide 3-kinase in podocytes","volume":"73","author":"Zhu","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.08.041_bib35","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/nm.3313","article-title":"AKT2 is essential to maintain podocyte viability and function during chronic kidney disease","volume":"19","author":"Canaud","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2025.08.041_bib36","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1002\/jcp.26222","article-title":"Comprehensive transcriptome analysis of fluid shear stress altered gene expression in renal epithelial cells","volume":"233","author":"Kunnen","year":"2018","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.kint.2025.08.041_bib37","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202300834R","article-title":"Flow induces common and specific transcriptional changes in renal tubular epithelial cells involving the PI3K pathway","volume":"38","author":"Tr\u00f6ndle","year":"2024","journal-title":"FASEB J"},{"key":"10.1016\/j.kint.2025.08.041_bib38","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ki.2008.160","article-title":"Activation of Erk1\/2 and Akt following unilateral ureteral obstruction","volume":"74","author":"Rodr\u00edguez-Pe\u00f1a","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.08.041_bib39","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.kint.2020.10.038","article-title":"Tubular mitochondrial AKT1 is activated during ischemia reperfusion injury and has a critical role in predisposition to chronic kidney disease","volume":"99","author":"Lin","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.08.041_bib40","doi-asserted-by":"crossref","first-page":"F215","DOI":"10.1152\/ajprenal.00548.2007","article-title":"Protein kinase B\/Akt activity is involved in renal TGF-\u03b21-driven epithelial-mesenchymal transition in vitro and in vivo","volume":"295","author":"Kattla","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2025.08.041_bib41","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.2337\/db05-1326","article-title":"Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN","volume":"55","author":"Mahimainathan","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2025.08.041_bib42","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1681\/ASN.2004100897","article-title":"Akt mediates mechanical strain-induced collagen production by mesangial cells","volume":"16","author":"Krepinsky","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.08.041_bib43","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.biocel.2006.08.004","article-title":"Role of the phosphatidylinositol 3-kinase and mTOR pathways in the regulation of renal fibroblast function and differentiation","volume":"39","author":"Winbanks","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.kint.2025.08.041_bib44","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ndt\/gfu196","article-title":"Potential role of Akt signaling in chronic kidney disease","volume":"30","author":"Lan","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.08.041_bib45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0898-6568(03)00094-9","article-title":"Tyrosine phosphorylation-dependent PI 3 kinase\/Akt signal transduction regulates TGF\u03b2-induced fibronectin expression in mesangial cells","volume":"16","author":"Ghosh Choudhury","year":"2004","journal-title":"Cell Signal"},{"key":"10.1016\/j.kint.2025.08.041_bib46","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1046\/j.1523-1755.2003.00204.x","article-title":"Renal ischemia\/reperfusion and ATP depletion\/repletion in LLC-PK1 cells result in phosphorylation of FKHR and FKHRL1","volume":"64","author":"Andreucci","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.08.041_bib47","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1440-1797.2006.00558.x","article-title":"Role of PI3-kinase\/Akt signalling pathway in renal function and cell proliferation after renal ischaemia\/reperfusion injury in mice","volume":"11","author":"Xie","year":"2006","journal-title":"Nephrology"},{"key":"10.1016\/j.kint.2025.08.041_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adq7825","article-title":"Podocyte-specific YAP activation triggers crescentic glomerulonephritis through cross-talk with parietal epithelial cells","volume":"17","author":"Turinsky","year":"2025","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.kint.2025.08.041_bib49","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1172\/JCI44771","article-title":"mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice","volume":"121","author":"Inoki","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2025.08.041_bib50","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/ndt\/gfq496","article-title":"The PI3K\/Akt\/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin","volume":"26","author":"Stylianou","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.08.041_bib51","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/labinvest.2011.43","article-title":"Role of amino acid transporter LAT2 in the activation of mTORC1 pathway and the pathogenesis of crescentic glomerulonephritis","volume":"91","author":"Kurayama","year":"2011","journal-title":"Lab Invest"},{"key":"10.1016\/j.kint.2025.08.041_bib52","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2215\/CJN.03751106","article-title":"High sirolimus levels may induce focal segmental glomerulosclerosis de novo","volume":"2","author":"Letavernier","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.08.041_bib53","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1056\/NEJM200511103531922","article-title":"Post-transplantation proteinuria and sirolimus","volume":"353","author":"Izzedine","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.08.041_bib54","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99271","article-title":"mTOR-mediated podocyte hypertrophy regulates glomerular integrity in mice and humans","volume":"4","author":"Puelles","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.kint.2025.08.041_bib55","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrneph.2016.108","article-title":"Roles of mTOR complexes in the kidney: implications for renal disease and transplantation","volume":"12","author":"Fantus","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2025.08.041_bib56","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri1056","article-title":"PI3K in lymphocyte development, differentiation and activation","volume":"3","author":"Okkenhaug","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.kint.2025.08.041_bib57","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nri.2016.93","article-title":"PI3K\u03b4 and primary immunodeficiencies","volume":"16","author":"Lucas","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.kint.2025.08.041_bib58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jaip.2023.09.016","article-title":"PI3K\u03b4 pathway dysregulation and unique features of its inhibition by leniolisib in activated PI3K\u03b4 syndrome and beyond","volume":"12","author":"Cant","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.kint.2025.08.041_bib59","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1182\/blood-2009-07-232330","article-title":"PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans","volume":"115","author":"Soond","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.kint.2025.08.041_bib60","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.3390\/ijms22126405","article-title":"The PI-3-kinase P110\u03b1 catalytic subunit of T lymphocytes modulates collagen-induced arthritis","volume":"22","author":"Montes-Casado","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2025.08.041_bib61","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fimmu.2014.00233","article-title":"Characterization of novel PI3K\u03b4 inhibitors as potential therapeutics for SLE and lupus nephritis in pre-clinical studies","volume":"5","author":"Haselmayer","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2025.08.041_bib62","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00204-023-03440-4","article-title":"Development and safety of PI3K inhibitors in cancer","volume":"97","author":"Yu","year":"2023","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.kint.2025.08.041_bib63","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2025.08.041_bib64","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1038\/s41467-024-51354-1","article-title":"A class I PI3K signalling network regulates primary cilia disassembly in normal physiology and disease","volume":"15","author":"Conduit","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2025.08.041_bib65","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2025.08.041_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2019.109468","article-title":"The PI3K\/Akt\/mTOR pathway in polycystic kidney disease: a complex interaction with polycystins and primary cilium","volume":"66","author":"Margaria","year":"2020","journal-title":"Cell Signal"},{"key":"10.1016\/j.kint.2025.08.041_bib67","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.08.041_bib68","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/j.1600-6143.2010.03152.x","article-title":"Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: what is the appropriate serum level?","volume":"10","author":"Canaud","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2025.08.041_bib69","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1038\/s41598-018-22938-x","article-title":"Dual mTOR\/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease","volume":"8","author":"Liu","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2025.08.041_bib70","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1681\/ASN.2015080906","article-title":"The Joubert syndrome protein Inpp5e controls ciliogenesis by regulating phosphoinositides at the apical membrane","volume":"28","author":"Xu","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.08.041_bib71","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.kint.2020.05.040","article-title":"The phosphoinositide 3-kinase inhibitor alpelisib restores actin organization and improves proximal tubule dysfunction in vitro and in a mouse model of Lowe syndrome and Dent disease","volume":"98","author":"Berquez","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.08.041_bib72","doi-asserted-by":"crossref","first-page":"R1009","DOI":"10.1152\/ajpregu.00809.2010","article-title":"The proximal tubule in the pathophysiology of the diabetic kidney","volume":"300","author":"Vallon","year":"2011","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.kint.2025.08.041_bib73","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1681\/ASN.2016090938","article-title":"Polycystic kidney disease without an apparent family history","volume":"28","author":"Iliuta","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.08.041_bib74","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1056\/NEJM199903043400905","article-title":"Mosaicism in tuberous sclerosis as a potential cause of the failure of molecular diagnosis","volume":"340","author":"Kwiatkowska","year":"1999","journal-title":"N Engl J Med"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825008373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825008373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:32:12Z","timestamp":1778941932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253825008373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0085253825008373"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2025.08.041","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug repurposing in PIK3CA-related overgrowth spectrum: breakthroughs from overgrowth syndromes to kidney disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2025.08.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}